학술논문

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Document Type
article
Author
Figlioli, GisellaBogliolo, MassimoCatucci, IreneCaleca, LauraLasheras, Sandra VizPujol, RoserKiiski, Johanna IMuranen, Taru ABarnes, Daniel RDennis, JoeMichailidou, KyriakiBolla, Manjeet KLeslie, GoskaAalfs, Cora MAdank, Muriel AAdlard, JulianAgata, SimonaCadoo, KarenAgnarsson, Bjarni AAhearn, ThomasAittomäki, KristiinaAmbrosone, Christine BAndrews, LesleyAnton-Culver, HodaAntonenkova, Natalia NArndt, VolkerArnold, NorbertAronson, Kristan JArun, Banu KAsseryanis, EllaAuber, BerndAuvinen, PäiviAzzollini, JacopoBalmaña, JudithBarkardottir, Rosa BBarrowdale, DanielBarwell, JulianBeane Freeman, Laura EBeauparlant, Charles JolyBeckmann, Matthias WBehrens, SabineBenitez, JavierBerger, RaananBermisheva, MarinaBlanco, Amie MBlomqvist, CarlBogdanova, Natalia VBojesen, AndersBojesen, Stig EBonanni, BernardoBorg, AkeBrady, Angela FBrauch, HiltrudBrenner, HermannBrüning, ThomasBurwinkel, BarbaraBuys, Saundra SCaldés, TrinidadCaliebe, AlmuthCaligo, Maria ACampa, DanieleCampbell, Ian GCanzian, FedericoCastelao, Jose EChang-Claude, JennyChanock, Stephen JClaes, Kathleen BMClarke, Christine LCollavoli, AnitaConner, Thomas ACox, David GCybulski, CezaryCzene, KamilaDaly, Mary Bde la Hoya, MiguelDevilee, PeterDiez, OrlandDing, Yuan ChunDite, Gillian SDitsch, NinaDomchek, Susan MDorfling, Cecilia Mdos-Santos-Silva, IsabelDurda, KatarzynaDwek, MiriamEccles, Diana MEkici, Arif BEliassen, A HeatherEllberg, CarolinaEriksson, MikaelEvans, D GarethFasching, Peter AFigueroa, JonineFlyger, HenrikFoulkes, William DFriebel, Tara MFriedman, EitanGabrielson, MarikeGaddam, PragnaGago-Dominguez, Manuela
Source
npj Breast Cancer. 5(1)
Subject
Health Services and Systems
Biomedical and Clinical Sciences
Health Sciences
Oncology and Carcinogenesis
Clinical Research
Genetics
Breast Cancer
Cancer
Genetic Testing
2.1 Biological and endogenous factors
Aetiology
ABCTB Investigators
GEMO Study Collaborators
KConFab
Cancer genetics
Clinical sciences
Oncology and carcinogenesis
Epidemiology
Language
Abstract
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.